Persistence With and Adherence to Paliperidone Palmitate Once-Monthly Injection for Schizophrenia Treatment in China and Japan

Wang, Huaning; Zhang, Yongjing; Liu, Jin; Chi, Rui; Wu, Tao; Zhang, Ting; Zhang, Lili; Jiang, Kun; Qiu, Hong; Dong, Wei; Si, Tianmei

doi:10.4088/jcp.20m13850

Cited by 5 publications

(10 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the aforementioned limitations, data from naturalistic studies (cohort and mirror studies), with PDC as a measure of compliance, consistently describe significantly better adherence patterns in subjects treated with PP compared to OA. Favourable adherence outcomes related to PP have been highlighted in all the studies selected, with similar results both in Asian 34 and US populations. [28][29][30][31][32][33][35][36][37] PP showed higher adherence rates when compared to first-generation 32 and second-generation antipsychotics.…”

Section: Discussionsupporting

confidence: 62%

“…Figure 1 reports a flowchart of all papers evaluated and included in this review. Ten studies were selected: nine retrospective cohort studies [28][29][30][31][32][33][34][35][36] and one mirror study. 37 Among these papers, two studies showed data on adherence patterns only 29,34 and eight studies presented data on adherence levels and other clinical outcomes.…”

Section: Resultsmentioning

confidence: 99%

“…Ten studies were selected: nine retrospective cohort studies [28][29][30][31][32][33][34][35][36] and one mirror study. 37 Among these papers, two studies showed data on adherence patterns only 29,34 and eight studies presented data on adherence levels and other clinical outcomes. 28,[30][31][32][33][35][36][37] Moreover, compliance patterns have been studied in subjects receiving exclusively PP1M in eight papers, [28][29][30]33,34,36,37 while two studies reported data on a population treated with different LAI, including PP1M.…”

Section: Resultsmentioning

confidence: 99%

“…37 Among these papers, two studies showed data on adherence patterns only 29,34 and eight studies presented data on adherence levels and other clinical outcomes. 28,[30][31][32][33][35][36][37] Moreover, compliance patterns have been studied in subjects receiving exclusively PP1M in eight papers, [28][29][30]33,34,36,37 while two studies reported data on a population treated with different LAI, including PP1M. 32,35 Finally, in all the studies, patients were treated with PP1M; no data on PP3M and PP6M were found (Table 1).…”

Section: Resultsmentioning

confidence: 99%

“…Similar results were also found in subjects who received PP1M within one month the first relapse of the disorder. 30 Moreover, no differences have been found when PP has been studied as the only index medication [28][29][30][31]33,34,36,37 or with other LAI. 32,35 Noteworthy, in the retrospective study by Pilon et al 35 the LAI higher adherence patterns were mainly driven by the PP1M cohort, whereas risperidone-LAI and aripiprazole-LAI compliance levels were similar to the OA group.…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Paliperidone Palmitate: A Breakthrough Treatment for Schizophrenia? A Review on Patient Adherence Levels, Healthcare Resource Utilization and Costs

Bramante¹,

Salvo²,

Maina³

et al. 2023

NDT

View full text Add to dashboard Cite

International guidelines suggest long-term antipsychotic therapies for treating schizophrenia; however, medication compliance remains a critical issue in schizophrenia. Paliperidone palmitate (PP) is a second-generation antipsychotic long-acting injectable (SGA-LAI) approved for the treatment of schizophrenia. To date, the majority of studies on PP compliance patterns did not use specific instruments to assess medications' adherence, have been performed in not naturalistic samples and present partially overlapping populations. We conducted a systematic review in which we aimed to review the current knowledge on PP-LAI adherence levels and to describe healthcare resource utilisation and costs related to PP-LAI treatment. The evaluation has been conducted by searching in different databases (PubMed, Ovid, Scopus, and Cochrane Library) from inception to September 2022. Our findings suggest that paliperidone palmitate should be considered a good treatment strategy for patients affected by schizophrenia: PP showed both a good efficacy and tolerability and better adherence patterns and more favourable healthcare resource utilisation and costs, compared to OA.

show abstract

Section: Discussionsupporting

confidence: 62%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Paliperidone Palmitate: A Breakthrough Treatment for Schizophrenia? A Review on Patient Adherence Levels, Healthcare Resource Utilization and Costs

Bramante¹,

Salvo²,

Maina³

et al. 2023

NDT

View full text Add to dashboard Cite

show abstract

Risk of Cardiovascular Events in Schizophrenic Patients Treated with Paliperidone Palmitate Once-Monthly Injection (PP1M): A Population-Based Retrospective Cohort Study in Taiwan

Shen,

Yan,

et al. 2024

Clin Drug Investig

Self Cite

View full text Add to dashboard Cite

Background Schizophrenia is one of the leading causes of disability. Paliperidone palmitate once-monthly injection (PP1M) was developed to provide consistent drug delivery and improve medication adherence for maintenance treatment. It is well known that patients with schizophrenia have higher cardiovascular risks, however little is known about the cardiovascular risks of patients with schizophrenia treated with PP1M in Asia. Objective This study aimed to estimate the incidence of cardiovascular events after initiating PP1M treatment and evaluate the cardiovascular risk associations compared with oral second-generation antipsychotics (SGAs). Methods Data from Taiwan's National Health Insurance Research Database were used to identify a cohort of adult patients with schizophrenia who received any SGAs from 1 March 2012 to 31 December 2018. Patients who initiated PP1M treatment were enrolled for descriptive analysis of incidence rates. PP1M patients were propensity matched 1:1 to patients initiating a new oral SGA, for comparative analysis based on demographics, clinical characteristics and treatment history at baseline, in three-step matching procedures, following the prevalent new-user design to enhance comparability. Follow-up ended at the end of the treatment episode of index drug, death, last record available, or end of the study (31 December 2019). Study endpoints included serious cardiovascular events (including severe ventricular arrhythmia and sudden death), expanded serious cardiovascular events (which further included acute myocardial infarction and ischemic stroke), and cardiovascular hospitalizations. Risks of study endpoints between matched cohorts were compared using Cox regression. Results Overall, 11,023 patients initiating PP1M treatment were identified (49.5% were females; mean age of 43.2 [12.2] years). Overall incidences for serious cardiovascular events, expanded serious cardiovascular events, and cardiovascular hospitalizations were 3.92, 7.88 and 51.96 per 1000 person-years, respectively. In matched cohort analysis (N = 10,115), the hazard ratios (HRs) between initiating PP1M and a new oral SGA for serious cardiovascular events, expanded serious cardiovascular events, and cardiovascular hospitalizations were 0.86 (95% confidence interval [CI] 0.55-1.36), 0.88 (95% CI 0.63-1.21), and 0.78 (95% CI 0.69-0.89), respectively. Conclusion This study reported the population-based incidence of cardiovascular events in schizophrenic patients initiating PP1M treatment. PP1M was not associated with increased risks of serious cardiovascular events but was potentially associated with lower risks of cardiovascular hospitalizations compared with oral SGAs.

show abstract

Nomogram model for predicting medication adherence in patients with various mental disorders based on the Dryad database

Pei,

Du,

Liu

et al. 2024

BMJ Open

View full text Add to dashboard Cite

ObjectiveTreatment compliance among psychiatric patients is related to disease outcomes. How to assess patient compliance remains a concern. Here, we established a predictive model for medication compliance in patients with psychotic disorders to provide a reference for early intervention in treatment non-compliance behaviour.DesignClinical information for 451 patients with psychotic disorders was downloaded from the Dryad database. The Least Absolute Shrinkage and Selection Operator regression and logistic regression were used to establish the model. Bootstrap resampling (1000 iterations) was used for internal validation and a nomogram was drawn to predict medication compliance. The consistency index, Brier score, receiver operating characteristic curve and decision curve were used for model evaluation.Setting35 Italian Community Psychiatric Services.Participants451 patients prescribed with any long-acting intramuscular (LAI) antipsychotic were consecutively recruited, and assessed after 6 months and 12 months, from December 2015 to May 2017.Results432 patients with psychotic disorders were included for model construction; among these, the compliance rate was 61.3%. The Drug Attitude Inventory-10 (DAI-10) and Brief Psychiatric Rating Scale (BPRS) scores, multiple hospitalisations in 1 year and a history of long-acting injectables were found to be independent risk factors for treatment noncompliance (all p<0.01). The concordance statistic of the nomogram was 0.709 (95% CI 0.652 to 0.766), the Brier index was 0.215 and the area under the ROC curve was 0.716 (95% CI 0.669 to 0.763); decision curve analysis showed that applying this model between the threshold probabilities of 44% and 63% improved the net clinical benefit.ConclusionA low DAI-10 score, a high BPRS score, multiple hospitalisations in 1 year and the previous use of long-acting injectable drugs were independent risk factors for medication noncompliance in patients with psychotic disorders. Our nomogram for predicting treatment adherence behaviour in psychiatric patients exhibited good sensitivity and specificity.

show abstract

Persistence With and Adherence to Paliperidone Palmitate Once-Monthly Injection for Schizophrenia Treatment in China and Japan

Cited by 5 publications

References 17 publications

Paliperidone Palmitate: A Breakthrough Treatment for Schizophrenia? A Review on Patient Adherence Levels, Healthcare Resource Utilization and Costs

Paliperidone Palmitate: A Breakthrough Treatment for Schizophrenia? A Review on Patient Adherence Levels, Healthcare Resource Utilization and Costs

Risk of Cardiovascular Events in Schizophrenic Patients Treated with Paliperidone Palmitate Once-Monthly Injection (PP1M): A Population-Based Retrospective Cohort Study in Taiwan

Nomogram model for predicting medication adherence in patients with various mental disorders based on the Dryad database

Contact Info

Product

Resources

About